PDS Biotechnology Corp (PDSB)
3.71
-0.25
(-6.31%)
USD |
NASDAQ |
Oct 04, 16:00
3.704
-0.01
(-0.16%)
After-Hours: 20:00
PDS Biotechnology SG&A Expense (Annual): 15.28M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.28M |
| December 31, 2022 | 12.24M |
| December 31, 2021 | 10.18M |
| December 31, 2020 | 6.978M |
| December 31, 2019 | 10.98M |
| December 31, 2018 | 14.29M |
| Date | Value |
|---|---|
| December 31, 2017 | 17.66M |
| December 31, 2016 | 14.69M |
| December 31, 2015 | 8.659M |
| December 31, 2014 | 4.721M |
| December 31, 2013 | 2.004M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
6.978M
Minimum
2020
15.28M
Maximum
2023
11.13M
Average
10.98M
Median
2019
SG&A Expense (Annual) Benchmarks
| Chimerix Inc | 24.60M |
| Marinus Pharmaceuticals Inc | 61.15M |
| Jaguar Health Inc | 23.05M |
| Seres Therapeutics Inc | 87.74M |
| Mersana Therapeutics Inc | 59.54M |